[Adverse effects of H. pylori eradication therapy and its measure].
Miwa
Hiroto
H
Department of Gastroenterology, Juntendo University School of Medicine.
Kurosawa
Akihiko
A
Sato
Nabuhiro
N
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D017291:Clarithromycin / Q000009:adverse effects* / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced / Q000517:prevention & control; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007779:Lactobacillus acidophilus; D064747:Lansoprazole; D009059:Mouth Diseases / Q000139:chemically induced / Q000517:prevention & control; D009853:Omeprazole / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole